Skip to main content
SGRY
NASDAQ Industrial Applications And Services

Surgery Partners Posts Q3 Loss, Suspends Guidance Ahead of $25/Share HealthSpan Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$26.55
Mkt Cap
$3.409B
52W Low
$11.41
52W High
$27.225
52W Position info
133% above low
Off High info
2.5% below high
Rel. Volume info
4.4× avg
Market data snapshot near publication time

SGRY has more than doubled off its 52-week low of $11.41 on elevated volume (4.4× avg).

Summary

Surgery Partners reported a $21.1M Q3 net loss on revenue of $815.3M and suspended guidance and its earnings call due to the pending HealthSpan buyout at $25.00 per share in cash.


Key Events · Earnings and Guidance · SGRY

  • Q3 Revenue Slips, Net Loss Widens

    Revenue fell 0.8% to $815.3M from $821.5M, and net loss attributable to Surgery Partners was $21.1M (-$0.16 per share) versus -$22.7M a year earlier.

  • Adjusted EBITDA Declines

    Adjusted EBITDA was $132.7M versus $136.4M in Q3 2025, a 16.3% margin; same-facility revenue grew 6.0% on 0.2% case growth.

  • Guidance and Earnings Call Suspended

    Citing the pending HealthSpan transaction, the company will not host an earnings call and will no longer provide forward-looking guidance.

  • Balance Sheet and Leverage

    Cash was $354.5M with $692.8M of revolver capacity at September 30, 2026; net debt to EBITDA was approximately 4.4x under the credit agreement.


Analysis · SGRY · Industrial Applications And Services

The merger headline was already out this morning, but the attached release carries the actual Q3 numbers: revenue slipped 0.8% to $815.3M and the company swung to a $21.1M net loss attributable to shareholders, with Adjusted EBITDA down to $132.7M from $136.4M. Management also stopped giving forward guidance and canceled the earnings call because of the pending takeover. That matters less for standalone valuation now — the $25.00 cash price is the anchor — and more as a check on whether the deal holds: same-facility revenue grew 6.0%, leverage sits at roughly 4.4x, and the amended agreement adds a 10% annual ticking fee if the merger has not closed by March 1, 2027, which puts pressure on both sides to finish in Q1 2027.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SGRY was trading at $26.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $11.41 to $27.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SGRY - Latest Insights

SGRY
Nov 09, 2026, 5:14 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.46
Real-time Price: $26.48 info
Change: +$0.0199 (+0.08%) info
Market Cap: $3.409B info
SGRY
Nov 09, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $25.80
Real-time Price: $26.48 info
Change: +$0.680 (+3%) info
Market Cap: $3.409B info
SGRY
Nov 09, 2026, 8:30 AM EST
Source: BusinessWire
Importance Score:
9
Price at Filing: $23.18
Real-time Price: $26.48 info
Change: +$3.30 (+14%) info
Market Cap: $3.409B info
SGRY
Oct 26, 2026, 9:05 AM EDT
Filing Type: DEFA14A
Importance Score:
10
Price at Filing: $19.47
Real-time Price: $26.48 info
Change: +$7.01 (+36%) info
Market Cap: $3.409B info
SGRY
Oct 26, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $19.47
Real-time Price: $26.48 info
Change: +$7.01 (+36%) info
Market Cap: $3.409B info